{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:26Z","timestamp":1790666966646,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chemotherapy for pediatric leukemia induces profound immunosuppression, resulting in waning protection against vaccine-preventable diseases. Despite high survival rates, standardized revaccination protocols for non-transplant survivors remain controversial. We aimed to assess the serologic immunity to measles, mumps, rubella, and varicella among pediatric leukemia survivors and to identify clinical and treatment-related determinants of immune persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 192 pediatric leukemia survivors treated with non-HSCT chemotherapy at Phoenix Children\u2019s Hospital (2021 to 2023) underwent serologic testing for measles, mumps, rubella, and varicella IgG antibodies. Demographic, clinical, and immunization data were retrieved from institutional and state registries. Associations between patient characteristics and serologic immunity were analyzed using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At a mean of 6.51 years following chemotherapy completion, the overall seropositivity rates were 37.0% for measles, 40.6% for mumps, 70.8% for rubella, and 24.5% for varicella. Survivors who received post-chemotherapy vaccination demonstrated significantly higher seropositivity for rubella (81.9% vs. 64.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004) and varicella (35.6% vs. 16.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.005), with higher but non-significant seropositivity for measles and mumps. Low-risk B-cell acute lymphoblastic leukemia (ALL) patients exhibited higher immunity compared with high-risk patients, with significant differences observed for mumps (53.6% vs. 24.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0009) and rubella (81.2% vs. 66.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.039). Moreover, a shorter interval from therapy completion was associated with improved rubella immunity (adjusted OR=0.753; 95% CI: 0.66-0.86). Post-chemotherapy revaccination was independently associated with increased odds of rubella (adjusted OR=4.89; 95% CI: 1.762-13.572) and varicella (adjusted OR=2.65; 95% CI: 1.124-6.26) immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Substantial attenuation of vaccine-derived immunity persists years after chemotherapy completion in pediatric leukemia survivors. Both treatment intensity and absence of post-chemotherapy revaccination contribute to impaired long-term humoral immunity. These findings support routine revaccinations for all non-transplant pediatric leukemia survivors and underscore the need for risk-adapted, individualized survivorship immunization strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003230","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:02:20Z","timestamp":1782766940000},"page":"e264-e272","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-837X","authenticated-orcid":false,"given":"Hussien Ahmed H.","family":"Abdelgawad","sequence":"first","affiliation":[{"name":"Center for Cancer and Blood Disorders, Phoenix Children\u2019s, Phoenix, AZ"},{"name":"Department of Child Health, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hinkle","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Phoenix Children\u2019s, Phoenix, AZ"},{"name":"Department of Child Health, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Fodor","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Phoenix Children\u2019s, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ritchey","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Phoenix Children\u2019s, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ostdiek","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Phoenix Children\u2019s, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Ballan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Phoenix Children\u2019s, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Phoenix Children\u2019s, Phoenix, AZ"},{"name":"Department of Child Health, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15585\/mmwr.mm6636a3","article-title":"Rates and Trends of pediatric acute lymphoblastic leukemia\u2014United States, 2001-2014","volume":"66","author":"Siegel","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/21645515.2020.1802975","article-title":"Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors","volume":"17","author":"Toret","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12887-024-05030-4","article-title":"Clinical analysis of immune reconstitution after chemotherapy in children with acute lymphoblastic leukemia","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Pediatr"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"e30133","DOI":"10.1002\/pbc.30133","article-title":"MMR vaccination timing and long-term immunity among childhood cancer survivors","volume":"70","author":"Speckhart","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1016\/j.vaccine.2014.04.042","article-title":"Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer","volume":"32","author":"Bochennek","year":"2014","journal-title":"Vaccine"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12519-023-00721-x","article-title":"Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis","volume":"19","author":"Wang","year":"2023","journal-title":"World J Pediatr"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2352-4642(20)30312-6","article-title":"Immune function in childhood cancer survivors: a Children\u2019s Oncology Group review","volume":"5","author":"Guilcher","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.22.00230","article-title":"A population-based study of the long-term risk of infections associated with hospitalization in childhood cancer survivors","volume":"41","author":"Chehab","year":"2023","journal-title":"J Clin Oncol"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"2108\u2013","DOI":"10.1002\/pbc.25685","article-title":"Vaccine-derived immunity in children with cancer\u2014analysis of anti-tetanus and anti-diphtheria antibodies changes after completion of antineoplastic therapy","volume":"62","author":"Januszkiewicz-Lewandowska","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/vaccines13060617","article-title":"Deficits in long-term vaccine immunity among childhood cancer survivors despite revaccination programs","volume":"13","author":"Zadruzny","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12887-019-1710-5","article-title":"Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s","volume":"19","author":"Geier","year":"2019","journal-title":"BMC Pediatr"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.vaccine.2017.12.075","article-title":"Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine","volume":"36","author":"Seagle","year":"2018","journal-title":"Vaccine"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cncr.20384","article-title":"Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy","volume":"101","author":"Zignol","year":"2004","journal-title":"Cancer"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12519-023-00721-x","article-title":"Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis","volume":"19","author":"Wang","year":"2023","journal-title":"World J Pediatr"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archpedi.161.3.294","article-title":"Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment","volume":"161","author":"LeBaron","year":"2007","journal-title":"Arch Pediatr Adolesc Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:10Z","timestamp":1787747590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003230","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"2026-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}